



genOway announces the success of its initial public offering on Alternext - NYSE Euronext.

Demand was over-subscribed 10.5 times

Lyon, France - May the 7th, 2007 – genOway, the biotechnology company developing genetically modified models for the industry, announces today the final details of its initial public offering (IPO) on Alternext - NYSE Euronext.

Thanks to its Alternext stock market listing, genOway raises a total of about €6.2 million following full exercise of the extension option but prior to deduction of commissions and fees associated with the offering. The offer price has been set at €4.96 per share.

The offering raised significant interest, with demand representing more than ten times the allotted amount for institutional investors. Likewise, the retail offering for individual investors was a success, with demand representing over twelve times the initial offering.

"We're delighted with the success of our stock market listing, and the demand expressed. More than 40 different investment funds from 4 countries in Europe are joining genOway" said Gilles de Poncins, the company's co-founder and CFO.

genOway's market listing and capital increase will provide the company with additional resources for supporting its growth strategy, which particularly aims at increasing its North-America and Asian market shares.

"Market listing is a key step in the life of the company. Today, genOway has a strong growth, a solid intellectual property portfolio and recognized, proven know-how & technologies. This new phase will enable the company to accelerate its development and to become the leading actor on its markets" added Alexandre Fraichard, genOway's co-founder and CEO

Practical information:

First trading day: Monday, May 7, 2007

ISIN Code: FR004053510

Ticker code: ALGEN

About genOway (www.genOway.com)

Based in Lyon, France, and established in 1999, genOway is a provider dedicated to the development of genetically modified mouse and rat models. The company has established business relationships with renowned academic research centers among which King's College London, Albert Einstein College of Medicine, Duke University Medical Center, Harvard Medical School, National Institutes of Health, Pasteur Institutes, University of Texas are a few to mention. The company works also with major biotech companies and leading pharmaceuticals companies: Altana Pharma, Bayer, Chiesi Farmaceutici, Galderma, GlaxoSmithKline, Johnson & Johnson, Laboratoires Servier, Merck Sharp & Dohme, Novartis, Novo Nordisk A/S, Pfizer, Schering A.G, Schering-Plough, Sepracor, etc.

With 50 full-time employees and clients in 22 countries in Europe, North America and Asia, genOway is, with respect to staff and clients, the largest company in its field in Europe. 40 experienced biologists (15 PhDs and 25 technicians) are exclusively concentrated on designing models, molecular biology, cell biology and embryology.

Contact for genOway:

Alexandre Fraichard *Chief Executive Officer*

Gilles de Poncins *Chief Financial Officer*

genOway – Head Office

Phone: +33 (0)4 37 65 41 00 Email: info@genoway.com